![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.235 | -4.94% | 4.52 | 4.35 | 4.69 | 4.75 | 4.36 | 4.75 | 212,429 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/4/2020 14:48 | Decent size volume still going through, surprised we haven't regained momentum after the spike down.Just a matter of time | ![]() cambradjones | |
30/4/2020 14:39 | An interesting article in today's Guardian on treatments for Coronavirus: "....But whether remdesivir works or not, there are still all those other possibilities on the horizon. The World Health Organization chose three other potential therapies in addition to remdesivir to back in its Solidarity trial, which is supporting patient studies all over the world. These are interferon beta-1a, a molecule that our immune system produces; lopinavir, an approved treatment for HIV; and chloroquine/hydroxyc | ![]() aquilla | |
30/4/2020 14:35 | If they're going to post it, means its considered safe. But we knew anyway | ![]() bobaxe1 | |
30/4/2020 14:34 | From Twitter Worth looking at Dr. Tom Wilkinson (lead of #SNG #Synairgen trial) - he is now also clinical academic lead for the Uk Government's ACCORD (ACcelerating COVID-19 dRug Development)...I suspect no coincidence...southa | slinkyj | |
30/4/2020 14:23 | thwarnts. Yes thanks. Just wished I'd sold my remaining holdings in tern first thing this morning and put it in here.Wouldn't that have been a good move !!!! | ![]() cambradjones | |
30/4/2020 14:22 | An FDA research article published yesterday looked at 19 potential treatments. Incidentally SNG was not looked at. And the result was that only Remdesivir stood out with potential. That leaves a fairly open goal for SNG even if it shows weak efficacy. "Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection" The Home Treatment news is unique in the world of COVID treatments as far as I know and the story could be picked up worldwide. I would be pleased to see Remdesivir approved since it sets out a roadmap for SNG to hopefully follow. Interesting times. | ![]() pdt | |
30/4/2020 14:15 | Would we be manufacturing SNG001 'IF' it was a no goer!! | ![]() bmnsa | |
30/4/2020 14:15 | Over at TERN | ![]() vitec | |
30/4/2020 14:13 | Where is mr Floyd Magic? Likya? Been a bit quiet, hope he's not out? | slinkyj | |
30/4/2020 14:12 | Exactly V. This would have been shelved before suggesting home trials if things were not extremely positive. If lockdowns are going to be eased, this is right here ready to help with the herd immunity stage, and any other lung issues going forward. | slinkyj | |
30/4/2020 14:11 | Wait to the media gets hold of this. It will get to the £1 purely on momentum buying. The difference is there is a real story here and it could potentially save millions of lives. That is the best story you can get and every man and his dog will want a piece of the action. Blimey, I am getting to sound like Likya/Wally!! | ![]() vitec | |
30/4/2020 14:09 | What about 360 mentioned | ![]() bobaxe1 | |
30/4/2020 14:08 | I am assuming 'home' means nursing homes and even in that environment, it is not clear how you set up and monitor a double blind trial. Very odd indeed - that latest change to SNG016 does not make sense to me. | ![]() toffeeman | |
30/4/2020 14:07 | Any outcome from 1 in 2 surviving ICU has to be good. This is more when then if for me that this will work. The evidence is mounting. | ![]() vitec | |
30/4/2020 14:06 | Lets hope so and keep buying on any pullback. | ![]() bmnsa | |
30/4/2020 14:03 | Also big pharmas are fishing for bios showing promise. Been some noise about that today. No one wants to be out the game and SNG are at the top of it right now. The world needs a great treatment otherwise people will be to scared to go out even after lock down. After all who wants to be a statistic in the next surge. I would feel much more comfortable knowing that there were some good treatments available to reduce the risk of serious complications. | slinkyj | |
30/4/2020 14:01 | FINNCAP “We reiterate our 120p target price with the prospect that this could rise by up to 240p on a positive outcome of first data readout.” We are at 64p ffs so a 100% upside if the first target is met and 375% if the 2nd target is met. | ![]() adorling | |
30/4/2020 14:00 | Are you feeling better today cambradjones,.. tern around hey | thwarnts | |
30/4/2020 13:58 | 75 have been dosed ie finished the treatment period of two weeksI suspect the next will be enrolled within next ten days, so last bits of data collected by 20th of May, then analyse and publish results first week of juneExtension to home use is a brilliant move, but the logistics of identifying such individuals will be difficult... Will it be candidates identified by GPs or those presenting to A&E but not deemed ill enough to be admitted (there are criteria that we use to admit to hospital... Basically low oxygen levels with the 'standard covid symptoms'Exciting timesJust upset I didn't top up today, when I planned to after yesterday's dropNever mindGLA | ![]() yet another final | |
30/4/2020 13:56 | Agree with slinkyj, rise into the close. | ![]() cambradjones | |
30/4/2020 13:50 | re equities , the thing is they (every gov) are throwing money at the problem and as they say , they will do everything it takes , lots of fomo kicking in too so gawd knows how high it'll bounce sorry for the off topic | ![]() d1nga | |
30/4/2020 13:49 | Already had an rns | ![]() bobaxe1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions